Actinorhodin is a blue-pigmented, redox-active secondary metabolite that is produced by the bacterium Streptomyces coelicolor. Although actinorhodin has been used as a model compound for studying secondary metabolism, its biological activity is not well understood. Indeed, redox-active antibiotics in general have not been widely investigated at the mechanistic level. In this work, we have conducted a comprehensive chemical genetic investigation of actinorhodin's antibacterial effect on target organisms. We find that actinorhodin is a potent, bacteriostatic, pH-responsive antibiotic. Cells activate at least three stress responses in the presence of actinorhodin, including those responsible for managing oxidative damage, protein damage and selected forms of DNA damage. We find that mutations in the Staphylococcus aureus walRKHI operon can confer low-level resistance to actinorhodin, indicating possible targeting of the cell envelope. Our study indicates a complex mechanism of action, involving multiple molecular targets, that is distinct from other antibiotics.
Introduction
Most antibiotics are derived from small molecules (<2500 Da) known as 'secondary metabolites', 'specialized metabolites' or 'natural products' that are produced by environmental microorganisms. The majority of these molecules target enzymes in one of four biological processes: cell wall synthesis (e.g., penicillin, vancomycin), transcription (e.g., rifampicin, streptolydigin), maintenance of DNA topology (e.g., novobiocin, coumermycin A1) or protein synthesis (e.g., streptomycin, tetracycline, erythromycin). In addition to these well-characterized antibiotics, many other secondary metabolites are known but not well understood. One group of antimicrobial secondary metabolites that falls into this category includes redox-active antibiotics which, for the most part, have not been subjected to detailed mode-ofaction investigation. For example, we do not know whether they have specific targets or simply damage cells by inflicting oxidative damage on multiple targets.
Actinorhodin is a blue-pigmented compound produced by Streptomyces coelicolor that has served as an outstanding model for the genetic and biochemical investigation of secondary metabolism. This includes seminal work on polyketide biosynthetic gene clusters (Fern andez-Moreno et al., 1991) , the generation of hybrid polyketides (Omura et al., 1986) , the regulation of biosynthetic genes by pathway-specific regulators (Fern andez-Moreno et al., 1991) , pleiotropic regulators of secondary metabolism (Floriano and Bibb, 1996; Aceti and Champness, 1998; Uguru et al., 2005; Rigali et al., 2008; Gao et al., 2012; Wang et al., 2013) , as well as the regulation of self-resistance in antibiotic producers (Tahlan et al., 2007 Willems et al., 2008; Xu et al., 2012; Mak et al., 2014) . Ironically, actinorhodin itself is not well understood. In the earliest reports, it was described as a weak antibacterial (Wright and Hopwood, 1976) ; however, there has been no progress toward discovering its molecular target(s) or mode of action.
Actinorhodin has three prominent chemical features. First, its pigmentation is pH-responsive (it is red at acidic pH and blue at basic pH) (Bystrykh et al., 1996) . Second, actinorhodin is redox active and can act in redox-cycling reactions. Specifically, reduction of the quinone groups can generate electrons that can interact with molecular oxygen, yielding superoxide radical anions (O 2010; Shin et al., 2011; Singh et al., 2013; Lee et al., 2015 Lee et al., , 2017 . Third, actinorhodin has been shown to act as an organocatalyst of oxidative reactions in vitro, catalyzing the conversion of L-ascorbic acid and L-cysteine with the concomitant production of H 2 O 2 (Nishiyama et al., 2014) . In that work, it was suggested that actinorhodin might kill bacteria via the accumulation of toxic concentrations of H 2 O 2 .
It is possible that actinorhodin's high degree of chemical reactivity has stood in the way of a fulsome investigation of its mechanism of action. This reactivity suggests that actinorhodin may be a member of the socalled Pan Assay INterference compoundS or PAINS. Due to their chemical reactivity, these molecules tend to exhibit low specificity and are therefore thought of as poor drug leads (Baell and Walters, 2014; Baell, 2016) . However, given the growing problem of antibiotic resistance, it seems prudent to consider antibiotics that were previously neglected. Even if these molecules do not themselves have potential as drug candidates, understanding their mechanism of action could lead to the discovery of new vulnerable points in cell physiology that could be exploited for drug development.
In this work, we have conducted the first comprehensive chemical genomic investigation of actinorhodin's antibacterial effect on target organisms. We demonstrate that actinorhodin is a potent, bacteriostatic and pH-responsive antibiotic. Cells respond to the presence of this molecule with a significant change in its transcriptome that includes the activation of responses to redox stress, protein damage, some forms of DNA damage, as well as several pathways in primary metabolism. The compound compromises nucleic acid and cell wall synthesis, and can inactivate enzymes, including DNA gyrase and topoisomerase IV, with some degree of specificity. Finally, we find that mutations in the Staphylococcus aureus walRKHI operon confer lowlevel resistance to actinorhodin, indicating that genes under the control of this system are involved in sensitivity to actinorhodin and that there may be molecular targets of the compound in the Gram-positive cell envelope. Our results are most consistent with a view in which actinorhodin causes growth cessation by compromising multiple molecular targets, most likely through oxidative damage.
Results

Actinorhodin is a potent bacteriostatic antibiotic
To investigate the molecular action of actinorhodin, we purified the compound from Streptomyces coelicolor strain M510 (see Experimental procedures) (Floriano and Bibb, 1996) . Using HPLC, LC-MS and spectrophotometric analyses, we judged the purified compound to be 91% pure and verified that it is devoid of any other known antibiotic compounds that are produced by S. coelicolor (Supporting Information Fig. S1 ). To determine whether the purified material had antibiotic activity, we carried out microtitre broth dilution assays and measured minimum inhibitory concentrations (MIC) against a panel of Grampositive and Gram-negative bacteria (Table 1) . In agreement with previous work, we found that actinorhodin had antibiotic activity against Staphylococcus aureus, although it is sixfold more potent than previously reported with an MIC of 4 mg ml 21 rather than 25-30 mg ml 21 (Wright and Hopwood, 1976) . Consistent with its spectral responses to pH (Bystrykh et al., 1996; Nishiyama et al., 2014) , we found that its antibacterial activity was also pH-responsive. The compound was most potent under acidic conditions, with a MIC of 0.25 mg ml 21 at pH 5.5
( Fig. 2A) . Intermediate antibiotic activity was present at neutral pH with a MIC of 4 mg ml 21 at pH 7.0. Its activity was lost under basic conditions, where the MIC was >64 mg ml 21 at pH 8.5. The growth of the control cultures in the absence of actinorhodin did not vary significantly across this pH range (data not shown), indicating that the observed bioactivity is a result from the action of actinorhodin and not from cells that were inherently compromised by acidity. It is possible that this pH responsiveness explains the discrepancy between this Fig. 2 . A. Dose-response curves of actinorhodin on cellular growth of S. aureus in response to pH. Percent (%) growth was calculated by normalizing the growth of actinorhodin-treated samples with that of solvent-treated samples. Data represent the mean of one representative experiment performed in triplicate; error bars indicate standard deviation. A summary of the effect of external pH on actinorhodin bioactivity against S. aureus is shown on the right. Minimum inhibitory concentration (MIC) was determined by broth microdilution. B. Actinorhodin is a bacteriostatic antibiotic. Time-dependent killing assays of S. aureus showing cell counts being maintained over time with actinorhodin treatment. Cells were grown to mid-log phase before being challenged with actinorhodin (at MIC and 23 MIC) or dioxane (solvent control). Two independent experiments were performed at pH 7.0, and the result from one representative experiment is shown above.
work and previous reports on actinorhodin's antibacterial properties. Alternatively, the discrepancy could be due to the difference in methodology where the previous report extrapolated actinorhodin's MIC using an agar plug assay. The fact that actinorhodin is more potent at low pH argues against the biological relevance of its in vitro organocatalyst activity, as this effect is more pronounced in alkaline pH (Nishiyama et al., 2014) . Actinorhodin also showed strong antibiotic activity against Bacillus subtilis, Micrococcus luteus and Listeria monocytogenes (all at 4 mg ml
21
), and a multidrugresistant strain of S. aureus (at 8 mg ml 21 ) ( Table 1 ).
The activity against S. aureus ATCC BAA-44 TM is intriguing because this strain is reported to be resistant to ampicillin, amoxicillin/clavulanic acid, ciprofloxacin, cephalothin, doxycycline, gentamicin, erythromycin, imipenem, methicillin, penicillin, tetracycline, oxacillin, azithromycin, clindamycin, ceftriaxone, rifampin, amikacin and tobramycin, suggesting that actinorhodin can bypass this resistance. Actinorhodin also exhibited antimicrobial activity against Gram-positive environmental bacteria. Of eight streptomycete species, actinorhodin had detectable antibacterial activity against four species (S. sp. SPB74, S. hygroscopicus, S. albus and S. viridochromogenes) but not against four others (S. roseosporus, S. sp. SPB78, S. pristinaespiralis, and S. ghanaensis) (Supporting Information Fig. S2 ). Actinorhodin did not inhibit the growth of any Gram-negative bacteria including Acinetobacter baumannii, Escherichia coli, Klebsiella pneumoniae and Pseudomonas aeruginosa (all MICs >32 mg ml 21 ). To determine if this is because the compound is unable to penetrate the outer membrane of Gram-negative bacteria, we tested actinorhodin against a hyperpermeable E. coli DbamB DtolC strain (King et al., 2014) and found that it too was unaffected by actinorhodin (MIC >32 mg ml 21 ). We also found that the compound was inactive against Mycobacterium smegmatis (MIC >32 mg ml 21 ), which has a cell wall that contains an outer mycolic acid layer. Actinorhodin was also inactive against the fungal eukaryotes Saccharomyces cerevisiae, Candida albicans and Cryptococcus neoformans (all MICs >32 mg ml 21 ).
These data demonstrate that actinorhodin's antibiotic activity is specific for Gram-positive bacteria. Finally, we found that actinorhodin is bacteriostatic rather than bactericidal, with a minimum bactericidal concentration (MBC) of >64 mg ml 21 against S. aureus.
We confirmed its bacteriostatic activity using timedependent killing assays, where cell counts were maintained over time with actinorhodin treatment (Fig. 2B) .
Together, these data demonstrate that actinorhodin is a potent, pH-sensitive, bacteriostatic antibiotic that is primarily active against Gram-positive bacteria including multidrug-resistant S. aureus.
A complex bacterial response to actinorhodin
Most antibiotics bind to molecular targets involved in DNA replication, RNA synthesis, translation or cell wall biosynthesis. To determine whether actinorhodin affects any of these macromolecular pathways, we measured the incorporation of 3 H-labelled uridine, thymidine, leucine and N-acetyl-D-glucosamine into cells. We observed three actinorhodin-induced effects (Fig. 3A) . First, we found that at 13 and 83 MIC, actinorhodin caused reduced incorporation of radiolabeled thymidine into DNA, indicating impaired DNA synthesis. Second, at 13 and 83 MIC, we observed a modest reduction in the incorporation of radiolabeled uridine into RNA, indicating impaired RNA synthesis. Third, at 1=83 and 13 MIC, we ) and valinomycin-treated cells (10 mM) using a potassium electrode. The result from two independent experiments, performed at pH 7.0, is shown above. observed increased incorporation of radiolabeled N-acetyl-D-glucosamine, while its corporation fell at a higher concentration (83 MIC). These data suggest a complex effect of actinorhodin that includes targeting of cellular functions at the level of the nucleic acids and the cell wall.
We also determined whether actinorhodin disrupts the cell membrane by monitoring potassium ion efflux in the presence of the molecule. We did not observe actinorhodin-induced efflux of potassium ions, indicating that actinorhodin does not depolarize the membrane, at least for potassium ions (Fig. 3B) .
The effect of actinorhodin on thymidine incorporation suggested compromised DNA synthesis. This can occur when enzymes that control DNA topology are targeted, for example by novobiocin (gyrase) or ciprofloxacin (topoisomerase IV and others). We therefore conducted cell-free topoisomerase supercoiling and relaxation assays using two type II topoisomerases from S. aureus: DNA gyrase and topoisomerase IV. As expected, DNA gyrase was able to introduce negative supercoils into a relaxed, circular DNA molecule and this activity could be inhibited by novobiocin -inhibition was evident at concentrations as low as 0.06 lM and was essentially complete at 2 lM (Fig. 4A) . Actinorhodin was also able to inhibit this enzyme, although only at very high concentrations, on the order of 100 lM to 300 lM (Fig. 4A) . Similarly, topoisomerase IV was able to relieve supercoiling from a circular DNA molecule and this activity could be inhibited by ciprofloxacin (Fig. 4B) . Likewise, actinorhodin was also able to inhibit this activity but again only at concentrations above 90 lM (Fig.  4B ). To determine whether there was any specificity to these effects, we also tested the effect of actinorhodin on an unrelated DNA modifying enzyme DNase I. Actinorhodin had no effect on the activity of this enzyme even at concentrations as high as 140 lM (Fig. 4C) .
Another means by which compounds can impede DNA synthesis is by intercalating into the DNA. To address this, we compared the ability of actinorhodin and two known DNA intercalators (doxorubicin and (top) and actinorhodin (bottom). B. Effects of actinorhodin on DNA relaxation by S. aureus topoisomerase IV in the presence of increasing concentrations of ciprofloxacin (top) and actinorhodin (bottom). C. Actinorhodin does not inhibit DNase I digestion of pIJ6902 plasmid. D: dioxane solvent control; E: EDTA control; P: pIJ6902 plasmid. D. DNA mobility shift assays. Linearized pUC18 plasmid (2.6 kb) was incubated with increasing concentrations of actinorhodin, doxorubicin and actinomycin D at pH 7.0, and subsequently analyzed on an agarose gel to observe DNA intercalation. M: 1kb ladder.
actinomycin D) to bind DNA using a gel mobility shift assay. DNA binding was evident at doxorubicin and actinomycin D concentrations of 1 lg ml 21 and 10 lg ml
21
( Fig. 4D ). Under these conditions, however, actinorhodin did not shift the mobility of the DNA, suggesting that it does not form a stable complex with DNA. These data demonstrate that while actinorhodin does not stably bind DNA, it has the capacity to damage some DNA modifying enzymes -including at least two that modulate DNA topology. We note that the actinorhodin concentration required to inhibit DNA gyrase and topoisomerase IV is significantly higher than the concentrations at which it altered [ 3 H]-thymidine incorporation and indeed, higher than its MIC against S. aureus cells. It is unclear therefore, whether these effects suggest DNA topology as a primary antimicrobial target of actinorhodin. However, they clearly demonstrate that actinorhodin can damage some proteins.
To take a more global view, we used RNA-seq to compare the transcriptomes of actinorhodin-and solvent control-treated S. aureus cells. Since actinorhodin is redox-active and other investigators suggested that its biological activity involves the generation of toxic levels of H 2 O 2 , we also conducted RNA-seq on cells treated with H 2 O 2 in parallel. Based on the growth inhibitory concentration, we treated mid-log phase cells with 4 mg ml 21 actinorhodin for 15 minutes, harvested RNA and subjected it to an RNA-seq protocol (see Experimental procedures; Supporting Information Fig. S3 ). Parallel cultures were treated with 10 mM H 2 O 2 for 15 minutes. Under the conditions we used, the effect of this treatment was a brief cessation of growth (less than 30 minutes) followed by which cells recovered and grew normally. Actinorhodin had a rapid and widespread influence on gene expression in S. aureus cells. In total, 329 genes were differentially expressed compared with solventtreated cells (with changes that were ! two-fold and adjusted P-values of 0.05). Expression levels were increased for 203 ORFs (Supporting Information Table  S1 ), and decreased for 126 ORFs (Supporting Information Table S2 ). We grouped the actinorhodin-influenced genes into functional categories based on eggNOG and GO annotations (UniProt Consortium, 2015; HuertaCepas et al., 2016) , and observed several categories of genes that were enriched.
One of the most striking effects was the induction of stress responses. Most notably, this included 20 oxidative stress response genes, the majority of which are involved in the detoxification of ROS and metal homeostasis (Table 2 ). This data is consistent with cells responding promptly to redox stress brought about by actinorhodin's oxidative effects. Second, we found that actinorhodin treatment caused upregulation of genes involved in heat shock and/or the repair of damaged or misfolded proteins. These include ctsR-mcsA-mcsBclpC operon (heat shock response), the hrcA-grpEdnaK-dnaJ-prmA operon (protein damage and misfolding), groEL and groES (also protein damage and misfolding) (Supporting Information Table S1 ). Third, and consistent with the possible targeting of DNA, actinorhodin induced the genes dinB and nth, which are involved in DNA repair. The dinB gene encodes DNA polymerase IV, which is involved in error-prone repair, while the nth gene encodes endonuclease III, which is involved in the removal of oxidized pyrimidines. Interestingly, we did not detect the upregulation of other SOS-response genes including recA, lexA, uvrA and uvrB (Cirz et al., 2007) , indicating that the DNA damage caused by actinorhodin may be relatively selective and/or an indirect effect. This lack of SOS response was also seen in B. subtilis, where we did not observe activation of dinC, a gene that is induced as part of the LexA-controlled SOS response in this bacterium ( Fig. 5 ; Au et al., 2005) . In addition to the stress responses, another 30% of the upregulated genes were involved in aspects of central metabolism. These induced genes were associated with processes such as fatty acid degradation, the pentose phosphate pathway, amino acid, carbohydrate, thiamine, riboflavin and tagatose-6-phosphate metabolism (Supporting Information Table S1 ). The upregulation of riboflavin metabolic genes is of particular interest since the expression of 16 flavoproteins was also increased (Table 3) . Flavoproteins can undergo autoxidation to generate ROS (Imlay, 2013) ; therefore, it is possible that this is an indirect means whereby actinorhodin could cause oxidative damage.
Of the genes that were downregulated after actinorhodin treatment, the largest subset was involved in translation and ribosome biogenesis (Supporting Information  Table S2 ). In particular, we found that 10 out of 20 small ribosomal subunit genes and 16 out of 33 large ribosomal subunit genes were downregulated by two-fold or greater. These effects were not sufficient to alter the incorporation of radiolabeled leucine on the time scale used in the macromolecular synthesis experiments, and may be the result of slower cellular growth or secondary effects of various stress responses.
Interestingly, we noted changes in expression of several cell envelope metabolic genes that are known to be under the control of the WalKR two-component system (Table 4) . WalKR controls genes involved in cell wall metabolism and is essential for cell viability in S. aureus cells (Martin et al., 1999; Dubrac et al., 2008) . Although the expression of walKR was unchanged, we identified 35 WalKR regulon genes in our actinorhodin-responsive transcriptome. Of these, 15 were previously shown to be directly controlled by the WalKR system (Dubrac and Msadek, 2004; Delaun e et al., 2012) . Strikingly, 7 of these 15 genes were peptidoglycan hydrolases such as the endopeptidase (encoded by lytM), putative transglycosylase (encoded by isaA) and putative amidases (encoded by ssaA, SAOUHSC_02576, SAOUHSC_02883, SAOUHSC_02855, SAOUHSC_00671). Except for one, all of these 
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peptidoglycan hydrolase genes were downregulated after actinorhodin treatment. This modification of peptidoglycan hydrolases suggests that the bacterial cell envelope plays a role in how bacteria respond to actinorhodin's action. It is unclear how this response relates to the increase in peptidoglycan synthesis that was observed in the macromolecular synthesis assays. In contrast to the effects of actinorhodin, we observed a more modest transcriptional response to H 2 O 2 , where 46 ORFs were induced and 35 ORFs were repressed with changes that were !1.5-fold and adjusted P-values of 0.05) (Supporting Information Tables S3 and S4 ). Of these, 22 H 2 O 2 -upregulated genes and five H 2 O 2 -downregulated genes were shared with the actinorhodin transcriptome. For instance, both H 2 O 2 and actinorhodin induced the expression of oxidative stress response genes and tagatose-6-phosphate metabolic genes. The rest of the H 2 O 2 -modulated genes appear unrelated to those whose expression was altered by actinorhodin (see highlighted genes in Supporting Information Tables S1-4). Furthermore, unlike actinorhodin, H 2 O 2 activated recA, uvrA, uvrB, sbcD and sbcC, indicating a broader spectrum of DNA damage. Finally, unlike actinorhodin, H 2 O 2 had no effect on genes involved in ribosome biogenesis.
These data demonstrate a complex bacterial response to actinorhodin that includes the activation of the redox stress response, damaged protein response and a highly selective component of the DNA damage response. The upregulation of metabolic genes could suggest damage to selected metabolic enzymes or the generation of reducing equivalents important for the repair of redox damage. It is also clear that the effect of (Dubrac and Msadek, 2004). actinorhodin is more complex than that of H 2 O 2 and that, even if actinorhodin can cause the accumulation of some level of H 2 O 2 inside the cell as previously suggested (Nishiyama et al., 2014) , this could not explain the antimicrobial activity of the compound.
Mutations in the WalKR two-component system confer actinorhodin resistance
To further explore how actinorhodin acts on bacterial cells, we generated actinorhodin-resistant mutants by serial passage of susceptible S. aureus through progressively increasing concentrations of actinorhodin (see Experimental procedures). We conducted four serialpassage experiments to generate separate lineages that we denoted A to D (Fig. 6A) . In total, we isolated 21 actinorhodin-resistant mutants: 5 in each of lineages A, B and C, and 6 in lineage D. The mutants exhibited MICs that ranged from 23 to 163 MIC (8 to 64 mg ml 21 respectively) relative to the parental strain (Table 5 , Supporting Information Fig. S4) . Growth of the mutants in the absence of actinorhodin was indistinguishable from that of the parent (data not shown). The mutants were susceptible to novobiocin, trimethoprim, rifampicin, tetracycline, chloramphenicol and vancomycin, although two lineage A mutants exhibited cross-resistance to vancomycin (four-fold MIC increase compared to parent), and the lineage D mutants exhibited cross-resistance to novobiocin (four-fold MIC increase compared to parent) ( Table 5 ). None of the mutations caused cells to shift the pH of the growth medium into the alkaline range (data not shown).
We sequenced and analyzed the genomes of all 21 actinorhodin-resistant mutants, as well as the parental strain, and identified genetic changes using the Geneious software (see Experimental Procedures). In most strains, there were multiple sequence alterations (Supporting Information Table S5 ). Strikingly, however, 19 of 21 mutants had sequence changes in the walRKHI operon (Fig. 6B) , including mutations that altered the sequence of the histidine kinase WalK, its target response regulator WalR and two proteins of unknown function, WalH and WalI. The fact that walK and walR are essential for viability suggests that none of the alleles are null mutations. There are no sequence changes that would be expected to prevent autophosphorylation by WalK or phosphotransfer from WalK to WalR. All mutants in lineages A and C contained single nucleotide changes that result in amino acid substitutions in WalK. The sequence changes were G533S for lineage A mutants and T217K for lineage C mutants. Lineage B mutants all contained single nucleotide changes that result in T101M substitutions in WalR. In some lineage D mutants, frameshift, nonsense or insertion mutations were detected in walH and walI. Interestingly, four mutants had only a single nucleotide change Information Table S5 ). These four mutants had actinorhodin MICs of 8 mg ml 21 , or two-fold reduced sensitivity to that of the parental strain, and all their resistance profiles were specific for actinorhodin with no cross-resistance to any of novobiocin, trimethoprim, rifampicin, tetracycline, chloramphenicol or vancomycin (Table 5 ).
Mutants having a higher level of actinorhodin resistance had accumulated secondary mutations in genes encoding a variety of proteins (RpoC, PrmA, SAOUHSC_00416, ParB, KtrD and SAOUHSC_02733) (Fig. 6C) . We note that none of these genes was transcriptionally affected in the RNA-seq investigation of actinorhodin-treated cells and it is unclear how any of these mutations enhance actinorhodin resistance. In contrast, at least 35 genes known to be in the WalKR regulon were either upregulated or downregulated in response to actinorhodin (Table 4) .
To further explore the possible role of WalKR, we examined the effect of inducing the expression of either the wildtype S. aureus walR allele (strain ST1035) or a gain-of-function allele that contains a phosphomimetic amino acid replacement (strain ST1034; WalR c ; D55E) (Delaun e et al., 2012) . While induction of the control strain (vector only; strain ST1033) had no effect on actinorhodin sensitivity, we found that induction of both the wildtype and gain-of-function walR allele reproducibly conferred greater sensitivity to actinorhodin, with an MIC of 2 mg ml 21 , while the MIC against the vector control strain remained unchanged at 4 mg ml 21 (Fig. 7A and Table 6 ). The fact that this effect was the same on expression of both the wild type and the phosphomimetic allele likely means that the wild type protein can autophosphorylate via small molecule phosphodonor as is the case for some other response regulators. Addition of greater inducer concentrations caused lethal overinduction of the walR gene, so we were unable to determine whether this would have conferred greater sensitization to actinorhodin. Nevertheless, the sensitivity observed was specific to actinorhodin, as induction did not alter the sensitivity of cells to any of novobiocin, trimethoprim, rifampicin, chloramphenicol or vancomycin for both strains (Table 6 ). Altogether, these data suggest that WalKR plays a part in the cell's response to actinorhodin. Interestingly, T101 mutations in WalR, as well as T217 mutations in WalK have been identified (in combination with other mutations) in clinical isolates of vancomycinintermediate S. aureus (VISA) (Hafer et al., 2012) . In B. subtilis, the T101 site in WalR can be phosphorylated by the kinase PrkC, activating the WalR regulon to regulate cell wall metabolism (Libby et al., 2015) .
Finally, other investigators have compared actinorhodin's physiological role to that of two other compounds: (i) pyocyanin, a redox-active natural product, and (ii) juglone, a redox-active organocatalyst ( Fig. 1A ; Dietrich et al., 2008; Nishiyama et al., 2014) . To determine whether the action of these molecules is related to that of actinorhodin, we carried out microtitre broth dilution assays and measured pyocyanin and juglone's MICs against wildtype S. aureus and several of our actinorhodin-resistant mutants. We found that the activity of pyocyanin and juglone was unchanged in the actinorhodin-resistant mutants with MICs of 16 mg ml 21 for both compounds (Fig. 7B) . Actinorhodin resistance is therefore most likely unique to the compound and not simply a resistance to any elevation of redox activity.
Discussion
Most of the well understood natural product antibiotics compromise the biosynthesis of peptidoglycan, DNA, RNA or proteins (Kohanski et al., 2010) . A small number of exceptions impair fatty acid biosynthesis (Wang et al., 2006) , glycine metabolism (Zlitni et al., 2013) or cell division (Haydon et al., 2008) . We have shown that actinorhodin behaves very differently from these 'canonical' antibiotics which have defined cellular targets and resistance determinants. We propose a complex mechanism of action where actinorhodin causes oxidative damage of multiple cellular targets in bacteria, including components of the DNA, proteins and cell envelope. The oxidation-related toxicity could result from direct modification of targets by actinorhodin, or indirect, resulting from the generation of ROS inside the cell. However, the fact that actinorhodin-resistant mutants are also not resistant to juglone or pyocyanin, which can also generate ROS, suggests that actinorhodin has some degree of specificity of action. Furthermore, the transcriptomic response of cells to the non-specific ROS H 2 O 2 is very different from that of actinorhodin, further supporting a more complex mechanism for the natural product. We hypothesize that actinorhodin targets more than one structure inside cells -the observation that it activates the unfolded protein response is consistent with this. We are intrigued by the in vitro sensitivity of DNA gyrase and topoisomerase IV to actinorhodin. However, while we would not rule these proteins out as in vivo targets, we suspect that they do not explain the compound's antibacterial activity as they would for ciprofloxacin. In fact, the transcriptomic data showing lack of activation of the full SOS response does not support the targeting of DNA topology as a primary mechanism of action for actinorhodin. This is further supported by the fact that, unlike ciprofloxacin, actinorhodin does not activate the SOS gene dinC in B. subtilis.
Our data reveal that the WalKR two-component system plays a role in sensitivity and resistance to actinorhodin. As noted previously, this effect is particularly interesting because vancomycin resistance correlates with wal mutations in clinical isolates of VISA (Howden et al., 2011; Shoji et al., 2011; Hafer et al., 2012) . Moreover, it has previously been shown that resistance to daptomycin can also be conferred by alterations in the walK gene (Friedman et al., 2006) . Indeed, some daptomycin-resistant mutants also had secondary mutations in the rpoC gene like some of our actinorhodinresistant mutants. While the authors of that work could not explain this connection conclusively, one suggestion that they made was that the mutations might alter global gene expression in such a way as to confer resistance to some antibiotics. Subsequent work demonstrated that daptomycin interacts primarily with the cell envelope, specifically the membrane (Pogliano et al., 2012) . In this regard, it is difficult to understand the lack of cross-resistance in our mutant strains, although this may simply reflect the varying antibiotic sensitivities of the genetic backgrounds in these different bodies of work. Regardless, the effects of the wal operon suggest that the cell envelope is a likely target of actinorhodin in addition to the other cellular constituents discussed above.
Experimental procedures
Strains, culture conditions and compounds
Strains and plasmids are listed in Supporting Information Table S6 . Bacterial strains were grown in LB medium (pH 7.0) at 378C unless indicated otherwise. Mycobacterium smegmatis was grown in Middlebrook 7H9 medium (SigmaAldrich) supplemented with Middlebrook ADC (SigmaAldrich) at 308C. Fungal strains were grown in YPD medium (pH 7.0) at 308C. All compounds used in this study were purchased from Sigma-Aldrich unless otherwise stated. Actinomycin D was a kind gift from Dr. Sheila PimentalElardo. Radioisotopes for macromolecular synthesis assays were purchased from Perkin Elmer.
Isolation and purification of actinorhodin
Isolation of actinorhodin was adapted from previous work (Taguchi et al., 2000) . S. coelicolor M510 was grown in actinorhodin production medium (Taguchi et al., 2000) at 308C for 7 days with shaking. Cells were harvested by centrifugation, washed with 1 M HCl, and stirred with 1 M NaOH. The supernatant was then collected and acidified to pH 3 with concentrated HCl to yield a red precipitate of crude actinorhodin. The precipitate was collected by centrifugation, lyophilized and purified by a sequential wash of methanol, acetonitrile and acetone. The resultant actinorhodin was resuspended in 1,4-dioxane and its purity was assessed using HPLC, MS and spectrophotometric analyses. LC conditions were as follows: Phenomenex Luna C18 column (2 x 150 mm, 5 mm, 100 Å ); solvents H 2 O with 0.5% acetic acid (A), and CH 3 CN with 0.5% acetic acid (B); 408C column temperature; flow rate of 0.2 ml min 21 ; 1:1 (A:B) isocratic run for 15 min. Mass spectrum of purified actinorhodin was recorded on a Waters Xevo G2-S QTof with an electrospray ionization source in the negative ion mode. Absorption spectrum of purified actinorhodin was recorded on the Biotek Epoch microplate spectrophotometer from 250 to 700 nm.
Susceptibility testing
MIC of antibiotics against tested organisms was determined using the standard microtitre broth dilution assay. MIC was defined as the lowest concentration of antibiotic that inhibited visible growth of the organism after 16 hours. To analyze the effect of pH on actinorhodin activity, microtitre broth dilution assays were performed and optical density was measured at 600 nm after 16 hours of incubation. Dose-response curves were plotted on GraphPad Prism 5. Kirby Bauer disk diffusion assays on R2YE agar were performed against tested streptomycete strains using actinorhodin (100 mg) and 1,4-dioxane (equivalent volume).
To determine the MBC for actinorhodin, S. aureus ATCC 29213 cells from the wells of a MIC microbroth dilution plate that had been incubated for 16 hours at 378C were plated on LB agar. Colonies on the plates were enumerated after incubation for 24 hours. The MBC is defined as the lowest concentration of antibiotic which resulted in a 99.9% reduction from the initial bacterial titer of the starting inoculum. Two independent experiments were performed in duplicate.
Time-dependent killing assays were performed by subculturing an overnight culture of S. aureus ATCC 29213 (1:100) and incubated with shaking until early exponential phase. Bacteria were challenged with either actinorhodin (at 13 and 23 MIC) or 1,4-dioxane (solvent control) and then continued to grow with shaking. At intervals, an aliquot of cells was removed, pelleted and resuspended with phosphate buffered saline. Serially diluted suspensions were then plated on LB agar and incubated overnight before colonies were counted.
Macromolecular synthesis assay
Inhibition of macromolecular synthesis by actinorhodin was monitored as described previously (Cunningham et al., 2013) . S. aureus ATCC 29213 cells, which were grown overnight in cation-adjusted Mueller Hinton broth (Difco), were subcultured 1:200 in pre-warmed defined growth media and grown to OD 600 5 0.4. Actinorhodin (at 1/83, 13 and 83 MIC) was then added to the cultures and incubated for 10 minutes with shaking. Labelling of DNA, RNA, protein and cell wall were subsequently performed by the addition of methyl-[ ), respectively. The reactions were incubated for 20 minutes at 378C with shaking before terminated by the addition of 30% trichloroacetic acid (TCA)/70% ethanol. Cells were harvested using a Millipore vacuum filtration manifold with glass fiber filters (Whatman), washed twice with 5% TCA and followed by one wash with 95% ethanol. The filters were dried and counted with Ultima Gold F scintillation fluid (Perkin Elmer) in a Beckman Coulter LS 6500 liquid scintillation counter.
Potassium efflux assay
An overnight culture of S. aureus ATCC 29213 was subcultured (1:200) and grown to mid-log phase. Cells were harvested and washed with SM buffer (100 mM NaCl, 10 mM MgSO 4 •7H 2 O, 50 mM Tris-HCl, pH 7.0). Cells were then resuspended in SM buffer before treatment with 25 mg ml 21 of actinorhodin, 1,4-dioxane (equivalent volume to actinorhodin), 10 mM valinomycin or DMSO (equivalent volume to valinomycin). Samples were incubated with shaking for 60 min. At 15, 30 and 60 min time intervals, samples were removed and pelleted to extract the supernatant. Potassium levels in the supernatant were measured using the Orion Potassium SureFlow Combination Electrode (ThermoFisher Scientific). Concentration of potassium in each sample was determined using a potassium standard curve. Bacterial DNA gyrase supercoiling and topoisomerase IV relaxation inhibition assays S. aureus DNA gyrase and topoisomerase IV assays were performed based on established protocols obtained from the supplier (Inspiralis Ltd.; Norwich, United Kingdom). After reactions were stopped, drop dialysis was performed using MF-Millipore membranes and 1X TE (10 mM TrisHCl, 1 mM EDTA, pH 8.0). Gel electrophoresis and visualization of results were subsequently performed on the samples as previously described. Novobiocin and ciprofloxacin were used as controls for the gyrase supercoiling and topoisomerase IV relaxation assays, respectively.
DNase I assays
Degradation of the pIJ6902 plasmid DNA was assayed in a reaction volume of 20 mL containing 150 ng pIJ6902 plasmid (Huang et al., 2005) . Compound titrations in 1,4-dioxane were added and reactions were initiated with 0.002 units of DNase I (ThermoFisher Scientific). The reaction was incubated for 15 min at 378C before being subjected to gel electrophoresis. 2.5 mM of EDTA was used as a control for the DNase I assay.
DNA intercalation assays
To determine if actinorhodin is a DNA intercalator, DNA mobility shift assays were performed as described previously using BamHI-linearized pUC18 plasmid (Furlan et al., 2002) . Known DNA intercalators doxorubicin and actinomycin D were used as controls.
Growth-inhibitory concentration studies
Growth-inhibitory concentration (GIC) of actinorhodin was assessed in order to select the concentration of actinorhodin to use for transcriptional profiling (Muthaiyan et al., 2008) . Briefly, an overnight culture of S. aureus ATCC 29213 was subcultured 1:100 and incubated with shaking until OD 600 $0.4. Actinorhodin (at 13, 23 and 53 MIC) or dioxane (solvent control) was then added to the culture and growth was measured at 600 nm at regular intervals with the Epoch spectrophotometer (Biotek). GIC was defined as the lowest concentration of antibiotic that inhibited the growth of bacteria at log phase.
Transcriptional profiling
An overnight culture of S. aureus ATCC 29213 was subcultured 1:100 and incubated with shaking until OD 600 $0.4. In duplicate, cultures were then challenged with 4 mg ml 21 of actinorhodin (based on the GIC study) or 10 mM of H 2 O 2 for 15 minutes. Control cultures were challenged with an equivalent volume of dioxane for 15 minutes. Total bacterial RNA was extracted from 1 ml of culture. Cells were first harvested by centrifugation at 5000 3 g for 5 minutes at 48C. The cells were washed with cold water and subsequently resuspended in Resuspension Buffer (10 mM TrisHCl pH 7.5; 30 mM MgCl 2 ; 30 mM NH 4 Cl) containing 500 mg ml 21 lysostaphin. Cells were lysed at 378C for 30 minutes before RNA was extracted and purified with the Qiagen RNeasy Mini kit as per the manufacturer's instructions. RNA was then treated with DNase I.
RNA-seq libraries were prepared using the NEBNext Ultra Directional RNA Library Preparation kit for Illumina after ribosomal depletion using the Ribo-Zero rRNA Removal (Bacteria) kit (Illumina). RNA quality control was performed using the Agilent 2100 BioAnalyzer. Sequencing was performed using v3 chemistry with paired-end 2 3 75 bp reads on the Illumina MiSeq platform. Library preparation and sequencing were conducted at the Farncombe Metagenomics Facility (McMaster University; Hamilton, Canada). Reads were aligned to the S. aureus ATCC 29213 reference (GenBank accession: GCA_001267715.1) using Bowtie 2 v2.2.8 (Langmead and Salzberg, 2012) and counted using HTSeq 0.6.1 (Anders et al., 2015) . Differentially expressed genes were identified using DESeq2 v3.4 (Love et al., 2014) . For actinorhodin-challenged cells, genes with an adjusted P-value of 0.05 and a fold-change of !2 were identified as being differentially expressed, while genes with an adjusted P-value of 0.05 and a fold-change of !1.5 were identified as being differentially expressed for H 2 O 2 -treated cells. Genes were functionally annotated and categorized using the eggNOG v4.5 and UniProt (for GO annotations) databases (UniProt Consortium, 2015; HuertaCepas et al., 2016) . RNA-seq data discussed here has been deposited in the NCBI's Gene Expression Omnibus and are accessible through GEO Series accession no. GSE97007
(https://www.ncbi.nlm.nih.gov/geo/query/acc. cgi?acc5GSE97007). Differentially expressed ORFs were cross-referenced with the S. aureus NCTC 8325 genome for ease of analysis.
LacZ reporter assays
Disk diffusion assays were performed on B. subtilis lacZ reporter strains using LB agar plates containing 8 lg ml 21 X-gal. To monitor the induction of SOS response, the B. subtilis reporter strain YB5018 (dinC-lacZ fusion) was tested (Jani et al., 2015) .
Resistance studies
To generate mutants with decreased susceptibility of actinorhodin, S. aureus ATCC 29213 was serially passaged starting from a subinhibitory concentration of actinorhodin (1/83 MIC) to supra-MIC concentration of actinorhodin (163 MIC) (see Fig. 6A schematic) . This process was repeated four times to generate four independent lineages (denoted A to D). After each passage, an aliquot of cells was plated on LB agar and incubated overnight. Colonies were selected and the MIC of actinorhodin was assessed by microtitre broth dilution assays as described previously. Once actinorhodin-resistant mutants were identified, MICs were determined against a panel of reference antibiotics to examine any antibiotic cross-resistance. Reference antibiotics include novobiocin, trimethoprim, rifampicin, tetracycline, chloramphenicol and vancomycin.
Whole-genome sequencing of actinorhodin-resistant mutants
Genomic DNA was isolated from wildtype S. aureus ATCC 29213 and 21 actinorhodin-resistant mutants using the GeneJet Genomic DNA Purification Kit (ThermoFisher Scientific) with one modification: lysostaphin solution (200 mg ml 21 lysostaphin, 10 mM EDTA and 20 mM Tris-HCl, pH 7.5) was used in place of Gram-positive bacteria lysis buffer for bacterial lysis. DNA concentration and purity were assessed using the Take3 plate (Biotek) before sequencing libraries were prepared with the Illumina Nextera XT kit. Whole-genome sequencing of samples was performed using v2 chemistry with paired-end 2 3 150 bp reads on the Illumina MiSeq platform. Both library preparation and genome sequencing were conducted at the Donnelly Sequencing Centre, University of Toronto (Toronto, Canada). Quality of reads was analyzed using FastQC (version 0.11.4; Babraham Bioinformatics [https://www.bioinformatics.babraham.ac.uk/projects/fastqc/]) and trimmed using Trim Galore (version 0.4.1; Babraham Bioinformatics [https://www.bioinformatics.babraham.ac.uk/projects/trim_ galore/]). Assembly and mapping of reads to S. aureus ATCC 29213 (GenBank accession: GCA_001267715.2), as well as identification of mutations, were performed using Geneious v9.0.5 (Biomatters Ltd.). Coverage above 103 and cut-off frequency of 75% were considered for the detection of mutations. ORFs with identified mutations were cross-referenced with the S. aureus NCTC 8325 genome for ease of analysis.
WalR studies
MICs of actinorhodin against ST1033, ST1034 and ST1035 (Supporting Information Table S6 ) were determined using the standard microtitre broth dilution assay. Expression of the walR alleles was induced by the addition of CdCl 2 (to a final concentration of 0.25 mM). MICs of novobiocin, trimethoprim, rifampicin, chloramphenicol and vancomycin against these strains were also assessed to examine any antibiotic cross-resistance.
